Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Bone Metastatic Breast Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) A diagnosis of breast cancer must have been histologically or cytologically confirmed at any time point and women or men with metastatic breast cancer with two or more bone metastases identified by 99mTc bone scintigraphy and/or CT, at least one of these bone lesions must not have been treated with prior radiation therapy. 2) Patients with non-bone metastases (in addition to bone metastases) are permitted. 3) Patients with hormone-receptor positive disease should have progressed on at least one prior line of hormone therapy and a CDK4/6 inhibitor in the metastatic setting to be eligible (except if patient had a contraindication or intolerable toxicity with the use of these agents).

You may not be eligible for this study if the following are true:

  • 1) Patients with HER2-positive breast cancer 2) Patients with peripheral neuropathy > grade 1 and patients who have not recovered from AEs due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia. 3) Patients who have had chemotherapy or immunotherapy with checkpoint inhibitor within 4 weeks prior to treatment. 4) Patient who receives radiation therapy or hormone therapy within 2 weeks prior to treatment are excluded.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.